Clinical Trial Update: A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating CagriSema vs placebo to reduce blood sugar and body weight in adults with Type 2 Diabetes on diet and exercise.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• CagriSema (cagrilintide/semaglutide)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED